Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from ZYNE

Zynerba Pharmaceuticals R&D Expenses For Q3 Reach $5M, Here Are The Details

Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE), released financial results for the third quarter ended September 30, 2022. Q3 2022 Financial Highlights

Benzinga · Nov 14, 2022

Zynerba Pharmaceuticals Enters Into Equity Purchase Agreement For Up To $20M

Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE), the leader in pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, has entered into an equity purchase agreement for up to $20 million with Lincoln Park Capital Fund, LLC (LPC), a Chicag

Benzinga · Jul 21, 2022

Zynerba's Cannabidiol Formulated Gel Shows Encouraging Action In Genetic Disease

Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) announced positive top-line results from the Phase 2 INSPIRE trial of Zygel (Transdermal CBD gel) on pediatric behavioral and emotional symptoms of 22q11.2 deletion syndrome. The total score and all five subscales of the Anxiety, Depression, and Mood Scale showed statistically significant improvements at 14 weeks of treatment compared…

Benzinga · Jun 22, 2022

From analysis to the latest developments in health,
read the most diverse news in one place.

Zynerba Pharmaceuticals Reveals Lower Net Loss For Q4 And Full Year 2021

Manufacturer of transdermal cannabinoid therapies for neuropsychiatric disorders, Zynerba Pharmaceuticals, Inc. Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) reported Tuesday financial results for the fourth quarter and full year ended December 31, 2021.

Benzinga · Mar 1, 2022

Zynerba Pharmaceuticals Completes Enrollment For CBD Transdermal Trial For 22q Deletion Syndrome

Manufacturer of transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, Zynerba Pharmaceuticals, Inc.

Benzinga · Feb 28, 2022

Cannabis Movers & Shakers: Cresco, Agricor & Botanacor, C3 Industries, Akanda, CULTA, OWP, Zynerba

Cresco Labs Taps Megan Kulick To Serve As VP Of Investor Relations

Benzinga · Feb 17, 2022

Zynerba Pharmaceuticals Names New CLO & Corporate Secretary

Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) has appointed Albert P. Parker, an accomplished industry executive with over 25 years of pharmaceutical, biotech and healthcare experience, as chief legal officer and corporate secretary.

Benzinga · Feb 15, 2022

Read news from The Economist, FT, and more,
with one subscription

Coverage From

Benzinga

Organisations

From analysis to the latest developments in health,
read the most diverse news in one place.

Topics

Read news from The Economist, FT, and more,
with one subscription

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.